Title: 2019 Global Market of Hepatitis C – Analysis of Antiviral Drugs
1Hepatitis C Therapeutics in Major Developed
Markets to 2019 Outstanding Recent Approvals
and Late-Stage Pipeline to Transform Clinical and
Commercial LandscapebyGBI Research
- Explore all reports for Hepatitis Drugs
market - _at_
- http//www.rnrmarketresearch.com/reports/life-scie
nces/pharmaceuticals/diseases-treatment/hepatitis-
drugs .
2Hepatitis C Therapeutics in Major Developed
Markets to 2019 Outstanding Recent Approvals
and Late-Stage Pipeline to Transform Clinical and
Commercial Landscape
- Research Report, has released the pharma report,
Hepatitis C Therapeutics in Major Developed
Markets to 2019 Outstanding Recent Approvals and
Late-Stage Pipeline to Transform Clinical and
Commercial Landscape. The current Hepatitis C
treatment landscape consists of a combination of
pegylated interferon, ribavirin and, in patients
infected with genotype 1 hepatitis C, one of two
direct-acting antiviral agents (DAAs). Products
with these mechanisms of action have performed
strongly in the commercial setting, with the
market leader Incivek (a DAA) having reached
blockbuster sales. - However, these products are very poorly tolerated
and only moderately efficacious. The approval of
the DAA Sovaldi in December 2013 changed this,
with a complete viral clearance being achieved in
close to 100 of patients and a much improved
adverse event profile compared to previous
standards of therapy. In patients with genotype 2
and 3 hepatitis C, Sovaldi does not need to be
administered with pegylated interferon. A number
of products in the late-stage pipeline, which
promise to be even more efficacious and safe are
anticipated to enter the market over the forecast
period, including several interferon-free
therapies for genotype 1-infected patients. As a
result of this, as well as an overall increase in
the treated population, Researcher believes the
global market has the potential to grow to a
value of 18.6 billion by 2019, more than
tripling the 2012 market value of 5.8 billion. - Inquire for Discount _at_
- http//www.rnrmarketresearch.com/contacts/discount
?rname148416 .
3Hepatitis C Therapeutics in Major Developed
Markets to 2019 Outstanding Recent Approvals
and Late-Stage Pipeline to Transform Clinical and
Commercial Landscape
- Scope
- A brief introduction to hepatitis C, including
the diseases pathogenesis, risk factors and
diagnosis, and detailed analyses of disease
epidemiology and treatment algorithms. - In-depth analysis of the major antiviral drugs
used in the treatment of hepatitis C, including
analyses of their safety, efficacy, treatment
patterns and strengths/weaknesses. Includes a
heat map that compares marketed drugs in terms of
safety and efficacy. - A comprehensive review of the pipeline for
hepatitis C therapies, including individual
analysis of a number of late-stage pipeline drugs
that are likely to enter the market during the
forecast period. The pipeline is analyzed by
phase distribution, molecule type and molecular
target. - In-depth clinical trial enrolment, trial duration
and program failure rate analyses for each
molecule type and mechanism of action.
Additionally, clinical trial endpoints and
certain selection criteria are analyzed in great
depth. This section also includes an additional
heat map regarding pipeline products, and a
direct cross-analysis against currently marketed
products. - Complete Report Available _at_
- http//www.rnrmarketresearch.com/hepatitis-c-thera
peutics-in-major-developed-markets-to-2019-outstan
ding-recent-approvals-and-late-stage-pipeline-to-t
ransform-clinical-and-commercial-landscape-market-
report.html .
4Hepatitis C Therapeutics in Major Developed
Markets to 2019 Outstanding Recent Approvals
and Late-Stage Pipeline to Transform Clinical and
Commercial Landscape
- Multi-scenario forecast data of the market to
2019, which takes into account the effects of the
introduction of new drugs, the expiry of key
patents on current drugs and the changes in
disease epidemiology across the key developed
markets US, Canada, Japan, Germany, UK, France,
Italy and Spain. - Discussion of the drivers and barriers for market
growth. - Analysis of licensing and co-development deals
occurring in the hepatitis C market. - Reasons to buy
- Understand the different types of hepatitis C
therapies and how treatment varies by genotype. - Understand the treatment algorithms and
guidelines related to hepatitis C, how they are
anticipated to change during the forecast period
and where opportunities and unmet needs lie. - Understand the vast scope of the pipeline,
including which molecule types and mechanisms of
action are most prominent. - Buy a copy of report _at_
- http//www.rnrmarketresearch.com/contacts/purchase
?rname148416 .
5Hepatitis C Therapeutics in Major Developed
Markets to 2019 Outstanding Recent Approvals
and Late-Stage Pipeline to Transform Clinical and
Commercial Landscape
- Observe trends in clinical trial duration and
size as clinical phase and molecule type varies.
Use the clinical trial failure rate analysis to
assess the risk profiles of current and/or future
developmental programs for hepatitis C
therapeutics. - Observe the shift in clinical trial endpoints
with each clinical Phase, and use this data to
potentially influence any future developmental
programs. Additionally, understand the trends in
enrolment by patient genotype. - Assess the potential clinical and commercial
impact of current late-stage pipeline molecules
and the points of opportunity which remain to be
capitalized upon. - Table of Contents
- 1 Table of Contents 51.1 List of Tables 81.2
List of Figures 9 - 2 Introduction 102.1 Signs and Symptoms 102.2
Etiology and Risk Factors 11 - Request Sample copy of this report _at_
- http//www.rnrmarketresearch.com/contacts/request
-sample?rname148416 .
6Hepatitis C Therapeutics in Major Developed
Markets to 2019 Outstanding Recent Approvals
and Late-Stage Pipeline to Transform Clinical and
Commercial Landscape
- For more details contact Mr. Priyank Tiwari
sales_at_rnrmarketresearch.com / 18883915441
RnR Market Research RnRMarketResearch.com, an
online repository of market research reports,
offers in-depth analysis of over 5000 market
segments. RnR Market Research library has
syndicated reports by leading market research
publishers across the globe.